Intracoronary Tirofiban on No-Reflow Phenomena
No-Reflow Phenomenon
About this trial
This is an interventional treatment trial for No-Reflow Phenomenon focused on measuring No-reflow phenomenon, tirofiban, intracoronary
Eligibility Criteria
Inclusion Criteria:
- Patients with ST-elevated myocardial infarction who developed no-reflow phenomena
Exclusion Criteria:
- Treatment with thrombolytic drugs in the previous 24 hours
- Known malignancy
- Pain to balloon time >6 hours
- Uncontrolled hypertension (>180/110 mmHg)
- Bleeding diathesis
- Thrombocytopenia
- End-stage liver disease
- Cardiogenic shock
- Renal failure
- Life expectancy of less than 1 year
- Contraindication for the use of tirofiban.
Sites / Locations
- Erciyes University School of Medicine
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Tirofiban group
Placebo group
If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary tirofiban (25 µgr/kg) was administered via the guiding catheter to the infarct related artery
If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary serum physiologic as placebo was administered via the guiding catheter to the infarct related artery